Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences
09/01/2022 - 08:00 AM
PALO ALTO, Calif. , Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management team will participate in the following upcoming investor conferences:
Citi's 17th Annual BioPharma Conference
Date: Thursday, September 8, 2022 Location: Boston, MA Format: One-on-one meetings H.C. Wainwright 24th Annual Global Investment Conference
Date & Time: Monday, September 12, 2022 at 2:00 p.m. ET Location: New York, NY Format: Company presentation and one-on-one meetings Baird Global Healthcare Conference
Date & Time: Wednesday, September 14, 2022 at 3:45 p.m. ET Location: New York, NY Format: Company presentation and one-on-one meetings A live webcast of each presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com . A replay of each presentation will be available on the website for at least 90 days.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com .
Contacts Investors:Sylvia Wheeler Wheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Media:Sarah Mathieson SVP, Corporate Affairssmathieson@eigerbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-three-upcoming-investor-conferences-301616160.html
SOURCE Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals Inc
EIGR Rankings
N/A Ranked by Stock Gains
EIGR Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Palo Alto
About EIGR
eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.